The new era of innovation
For much of the past decade the pace of innovation underwhelmed many people—especially those miserable economists. Productivity growth was lacklustre and the most popular new inventions, the smartphone and social media, did not seem to help much. Their malign side-effects, such as the creation of powerful monopolies and the pollution of the public square, became painfully apparent. Promising technologies stalled, including self-driving cars, making Silicon Valley’s evangelists look naive. Security hawks warned that authoritarian China was racing past the West and some gloomy folk warned that the world was finally running out of useful ideas.
Today a dawn of technological optimism is breaking. The speed at which covid-19 vaccines have been produced has made scientists household names. Prominent breakthroughs, a tech investment boom and the adoption of digital technologies during the pandemic are combining to raise hopes of a new era of progress: optimists giddily predict a “roaring Twenties”. Just as the pessimism of the 2010s was overdone—the decade saw many advances, such as in cancer treatment—so predictions of technological Utopia are overblown. But there is a realistic possibility of a new era of innovation that could lift living standards, especially if governments help new technologies to flourish.
In the history of capitalism rapid technological advance has been the norm. The 18th century brought the Industrial Revolution and mechanised factories; the 19th century railways and electricity; the 20th century cars, planes, modern medicine and domestic liberation thanks to washing machines. In the 1970s, though, progress—measured by overall productivity growth—slowed. The economic impact was masked for a while by women piling into the workforce, and a burst of efficiency gains followed the adoption of personal computers in the 1990s. After 2000, though, growth flagged again.
There are three reasons to think this “great stagnation” might be ending. First is the flurry of recent discoveries with transformative potential. The success of the “messenger rna” technique behind the Pfizer-BioNTech and Moderna vaccines, and of bespoke antibody treatments, shows how science continues to empower medicine. Humans are increasingly able to bend biology to their will, whether that is to treat disease, edit genes or to grow meat in a lab. Artificial intelligence is at last displaying impressive progress in a range of contexts. A program created by DeepMind, part of Alphabet, has shown a remarkable ability to predict the shapes of proteins; last summer Openai unveiled gpt-3, the best natural-language algorithm to date; and since October driverless taxis have ferried the public around Phoenix, Arizona. Spectacular falls in the price of renewable energy are giving governments confidence that their green investments will pay off. Even China now promises carbon neutrality by 2060.
The second reason for optimism is booming investment in technology. In the second and third quarters of 2020 America’s non-residential private sector spent more on computers, software and research and development (R&D) than on buildings and industrial gear for the first time in over a decade. Governments are keen to give more cash to scientists. Having shrunk for years, public R&D spending across 24 OECD countries began to grow again in real terms in 2017. Investors’ enthusiasm for technology now extends to medical diagnostics, logistics, biotechnology and semiconductors. Such is the market’s optimism about electric vehicles that Tesla’s CEO, Elon Musk, who also runs a rocket firm, is the world’s richest man.
The third source of cheer is the rapid adoption of new technologies. It is not just that workers have taken to videoconferencing and consumers to e-commerce—significant as those advances are, for example to easing the constraints on jobseeking posed by housing shortages. The pandemic has also accelerated the adoptions of digital payments, telemedicine and industrial automation. It has been a reminder that adversity often forces societies to advance. The fight against climate change and the great-power competition between America and China could spur further bold steps.
Alas, innovation will not allow economies to shrug off the structural drags on growth. As societies get richer they spend a greater share of their income on labour-intensive services, such as restaurant meals, in which productivity growth is meagre because automation is hard. The ageing of populations will continue to suck workers into low-productivity at-home care. Decarbonising economies will not boost long-term growth unless green energy realises its potential to become cheaper than fossil fuels.
Yet it is reasonable to hope that a fresh wave of innovation might soon reverse the fall in economic dynamism which is responsible for perhaps a fifth of the 21st century’s growth slowdown. Over time that would compound into a big rise in living standards. Perhaps still more is achievable because many service industries, including health care and education, would benefit greatly from more innovation. Eventually, synthetic biology, artificial intelligence and robotics could up-end how almost everything is done.
It’s not rocket science
Although the private sector will ultimately determine which innovations succeed or fail, governments also have an important role to play. They should shoulder the risks in more “moonshot” projects. The state can usefully offer more and better subsidies for R&D, such as prizes for solving clearly defined problems. The state also has a big influence over how fast innovations diffuse through the economy. Governments need to make sure that regulation and lobbying do not slow down disruption, in part by providing an adequate safety-net for those whose livelihoods are upended by it. Innovation is concentrated among too few firms. Ensuring that the whole economy harnesses new technologies will require robust antitrust enforcement and looser intellectual-property regimes. If governments rise to the challenge, then faster growth and higher living standards will be within their reach, allowing them to defy the pessimists. The 2020s began with a cry of pain but, with the right policies, the decade could yet roar.
Read more: Cyber Monday is now every day
© [Jan 2021] The Economist Newspaper Limited. All rights reserved. From The Economist, published under license. The original article can be found at: https://www.economist.com/leaders/2021/01/16/why-a-dawn-of-technological-optimism-is-breaking
Not for Retail distribution: This document is intended exclusively for Professional, Institutional, Qualified or Wholesale Clients / Investors only, as defined by applicable local laws and regulation. Circulation must be restricted accordingly.
This document is for informational purposes only and does not constitute investment research or financial analysis relating to transactions in financial instruments as per MIF Directive (2014/65/EU), nor does it constitute on the part of AXA Investment Managers or its affiliated companies an offer to buy or sell any investments, products or services, and should not be considered as solicitation or investment, legal or tax advice, a recommendation for an investment strategy or a personalized recommendation to buy or sell securities.
Due to its simplification, this document is partial and opinions, estimates and forecasts herein are subjective and subject to change without notice. There is no guarantee forecasts made will come to pass. Data, figures, declarations, analysis, predictions and other information in this document is provided based on our state of knowledge at the time of creation of this document. Whilst every care is taken, no representation or warranty (including liability towards third parties), express or implied, is made as to the accuracy, reliability or completeness of the information contained herein. Reliance upon information in this material is at the sole discretion of the recipient. This material does not contain sufficient information to support an investment decision.
Issued in the UK by AXA Investment Managers UK Limited, which is authorised and regulated by the Financial Conduct Authority in the UK. Registered in England and Wales, No: 01431068. Registered Office: 22 Bishopsgate, London, EC2N 4BQ.
In other jurisdictions, this document is issued by AXA Investment Managers SA’s affiliates in those countries.
© 2021 AXA Investment Managers. All rights reserved